Servier takes option on GeNeuro's MS therapy

GeNeuro S.A. (Geneva, Switzerland) granted Servier (Neuilly-sur-Seine, France) an option to license worldwide rights, excluding the U.S. and Japan, to GNbAC1 to treat multiple sclerosis (MS).

Servier will pay GeNeuro $47 million up front for the option, and can exercise the option after GeNeuro completes a Phase IIb trial of the humanized mAb targeting the envelop protein of human endogenous retrovirus type W (HERV-W). ...